Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02139371
Overview
The primary objective of the study is to test a new radiotracer called 64Cu-DOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and less aggressive tumors. This is a first in human study to test the radiotracer in cancer patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging (1,3 and 24 hours post injection).
Phase
Early Phase 1
Contacts
Dorthe Skovgaard, MD, Phd (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT02139371Drug / Compound
Eligibility
Help us improve your experience